Literature DB >> 28196429

Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.

John Munkhaugen1, Elise Sverre1,2, Jan E Otterstad3, Kari Peersen3,4, Erik Gjertsen1, Joep Perk5, Lars Gullestad4, Torbjørn Moum2, Toril Dammen2, Einar Husebye1.   

Abstract

Objective Understanding the determinants of low-density lipoprotein cholesterol (LDL-C) control constitutes the basis of modelling interventions for optimal lipid control and prognosis. We aim to identify medical and psychosocial (study) factors associated with unfavourable LDL-C control in coronary patients. Methods A cross-sectional explorative study used logistic and linear regression analysis to investigate the association between study factors and LDL-C in 1095 patients, hospitalized with myocardial infarction and/or a coronary revascularization procedure. Data were collected from hospital records, a comprehensive self-report questionnaire, clinical examination and blood samples after 2-36 months follow-up. Results Fifty-seven per cent did not reach the LDL-C target of 1.8 mmol/l at follow-up. Low socioeconomic status and psychosocial factors were not associated with failure to reach the LDL-C target. Statin specific side-effects (odds ratio 3.23), low statin adherence (odds ratio 3.07), coronary artery by-pass graft operation as index treatment (odds ratio 1.95), ≥ 1 coronary event prior to the index event (odds ratio 1.81), female gender (odds ratio 1.80), moderate- or low-intensity statin therapy (odds ratio 1.62) and eating fish < 3 times/week (odds ratio 1.56) were statistically significantly associated with failure to reach the LDL-C target, in adjusted analyses. Only side-effects (standardized β 0.180), low statin adherence ( β 0.209) and moderate- or low-intensity statin therapy ( β 0.228) were associated with LDL-C in continuous analyses. Conclusions Statin specific side-effects, low statin adherence and moderate- or low-intensity statin therapy were the major factors associated with unfavourable LDL-C control. Interventions to improve LDL-C should ensure adherence and prescription of sufficiently potent statins, and address side-effects appropriately.

Entities:  

Keywords:  Secondary prevention; coronary heart disease; drug adherence; low-density lipoprotein cholesterol; psychosocial factors

Mesh:

Substances:

Year:  2017        PMID: 28196429     DOI: 10.1177/2047487317693134

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  10 in total

1.  Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.

Authors:  Safi U Khan; Muhammad U Khan; Shahul Valavoor; Muhammad Shahzeb Khan; Victor Okunrintemi; Mamas A Mamas; Thorsten M Leucker; Michael J Blaha; Erin D Michos
Journal:  Eur J Prev Cardiol       Date:  2019-09-02       Impact factor: 7.804

2.  Exploring the relationship between coronary heart disease and type 2 diabetes: a cross-sectional study of secondary prevention among diabetes patients.

Authors:  Bjørn Gjelsvik; Anh Thi Tran; Tore J Berg; Åsne Bakke; Ibrahimu Mdala; Kjersti Nøkleby; John G Cooper; Tor Claudi; Karianne Fjeld Løvaas; Geir Thue; Sverre Sandberg; Anne K Jenum
Journal:  BJGP Open       Date:  2019-03-20

Review 3.  Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review.

Authors:  Romeo-Gabriel Mihăilă
Journal:  Curr Cardiol Rev       Date:  2020

4.  Trends of Clinical Outcomes and Health Care Resource Use in Heart Failure in the United States.

Authors:  Safi U Khan; Muhammad Zia Khan; Mohamad Alkhouli
Journal:  J Am Heart Assoc       Date:  2020-07-04       Impact factor: 5.501

5.  Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Tromsø 7.

Authors:  Elisabeth Pedersen; Beate Hennie Garcia; Kjell H Halvorsen; Anne Elise Eggen; Henrik Schirmer; Marit Waaseth
Journal:  BMC Cardiovasc Disord       Date:  2021-01-21       Impact factor: 2.298

6.  Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects.

Authors:  Kari Peersen; John Munkhaugen; Elise Sverre; Oscar Kristiansen; Morten Fagerland; Nils Tore Vethe; Joep Perk; Einar Husebye; Toril Dammen
Journal:  BMC Cardiovasc Disord       Date:  2021-12-16       Impact factor: 2.298

7.  Medication adherence among persons with coronary heart disease and associations with blood pressure and low-density-lipoprotein-cholesterol.

Authors:  Elisabeth Pedersen; Raul Primicerio; Kjell H Halvorsen; Anne Elise Eggen; Beate Hennie Garcia; Henrik Schirmer; Marit Waaseth
Journal:  Eur J Clin Pharmacol       Date:  2022-01-21       Impact factor: 2.953

Review 8.  New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.

Authors:  Xin Su; Dao-Quan Peng
Journal:  Lipids Health Dis       Date:  2018-01-15       Impact factor: 3.876

9.  A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease.

Authors:  Oscar Kristiansen; Nils T Vethe; Morten W Fagerland; Stein Bergan; John Munkhaugen; Einar Husebye
Journal:  Br J Clin Pharmacol       Date:  2019-11-03       Impact factor: 4.335

Review 10.  Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).

Authors:  David Sinning; Ulf Landmesser
Journal:  Curr Cardiol Rep       Date:  2020-10-21       Impact factor: 2.931

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.